Ribonucleotide Reductase Immunoreactivity in Adenocarcinoma Cells and Malignant or Reactive Mesothelial Cells in Serous Effusions | Citedby Results | Acta Cytologica | Karger Publishers

Skip to Main Content

Skip Nav Destination

Ribonucleotide Reductase Immunoreactivity in Adenocarcinoma Cells and Malignant or Reactive Mesothelial Cells in Serous Effusions

Acta Cytologica (2003) 47 (2): 209–215.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia

Rebecca B. Klisovic
William Blum
Zhongfa Liu
Zhiliang Xie
Cheryl Kefauver
Lenguyen Huynh
James A. Zwiebel
Steven M. Devine
John C. Byrd
Michael R. Grever
Kenneth K. Chan
Guido Marcucci

Leukemia & Lymphoma (2014) 55 (6): 1332.

The Efficacy of the Ribonucleotide Reductase Inhibitor Didox in Preclinical Models of AML

Guerry J. Cook
David L. Caudell
Howard L. Elford
Timothy S. Pardee
Francesco Bertolini

PLoS ONE (2014) 9 (11): e112619.

Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia

Rebecca B. Klisovic
William Blum
Xiaohui Wei
Shujun Liu
Zhongfa Liu
Zhiliang Xie
Tamara Vukosavljevic
Cheryl Kefauver
LeNguyen Huynh
Jiuxia Pang
James A. Zwiebel
Steven Devine
John C. Byrd
Michael R. Grever
Kenneth Chan
Guido Marcucci

Clinical Cancer Research (2008) 14 (12): 3889.

The changes of gene expression profiles in hydatidiform mole and choriocarcinoma with hyperplasia of trophoblasts

J. Q. Cui
Y. F. Shi
H. J. Zhou
J. Q. Li

International Journal of Gynecological Cancer (2004) 14 (5): 984.